Acasti Pharma – Consensus Indicates Potential 260.0% Upside

Broker Ratings

Acasti Pharma with ticker code (ACST) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 3.15 and 1.89 with the average target price sitting at 2.52. Given that the stocks previous close was at 0.7 this would imply there is a potential upside of 260.0%. There is a 50 day moving average of 0.34 and the 200 day moving average is 0.4. The market capitalisation for the company is $62m. Company Website:

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index